Agenus
Agenus
AGEN
NASDAQ
1.92
USD
3.23%
About
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.).
Its primary focus is I-O, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody (AGEN1811)) and balstilimab (a programmed death receptor-1 (PD-1) blocking antibody).
Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 420.0K |
| Three Month Average Volume | 16.4M |
| High Low | |
| Fifty-Two Week High | 28.9 USD |
| Fifty-Two Week Low | 4.41 USD |
| Fifty-Two Week High Date | 01 Sep 2023 |
| Fifty-Two Week Low Date | 14 Aug 2024 |
| Price and Volume | |
| Current Price | 5.15 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -13.41% |
| Thirteen Week Relative Price Change | -69.33% |
| Twenty-Six Week Relative Price Change | -64.52% |
| Fifty-Two Week Relative Price Change | -85.11% |
| Year-to-Date Relative Price Change | -73.74% |
| Price Change | |
| One Day Price Change | 3.21% |
| Thirteen Week Price Change | -67.18% |
| Twenty-Six Week Price Change | -60.99% |
| Five Day Price Change | -11.21% |
| Fifty-Two Week Price Change | -81.34% |
| Year-to-Date Price Change | -68.90% |
| Month-to-Date Price Change | -14.74% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | -8.13093 USD |
| Book Value Per Share (Most Recent Quarter) | -11.42234 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | -9.60841 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | -12.78955 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -4.97785 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 8.73533 USD |
| Revenue Per Share (Trailing Twelve Months) | 8.02757 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -13.74583 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -11.26972 USD |
| Normalized (Last Fiscal Year) | -13.74583 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -13.74583 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -11.26972 USD |
| Including Extraordinary Items (Last Fiscal Year) | -13.74583 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -11.26972 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 3.8598 USD |
| Cash Per Share (Most Recent Quarter) | 4.43633 USD |
| Cash Flow Per Share (Last Fiscal Year) | -13.63898 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -10.90209 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -9.36254 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -83 |
| Cash Flow Revenue (Trailing Twelve Months) | -117 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -144.94% |
| Pretax Margin (Last Fiscal Year) | -164.69% |
| Pretax Margin (5 Year) | -102.92% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 98.01% |
| Gross Margin (Trailing Twelve Months) | 99.51% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -102.07% |
| Operating Margin (Trailing Twelve Months) | -71.18% |
| Operating Margin (5 Year) | -63.31% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -164.69% |
| Net Profit Margin (Trailing Twelve Months) | -144.94% |
| Net Profit Margin (5 Year) | -102.92% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -7.06% |
| Revenue Growth (3 Year) | 33.56% |
| Revenue Change (Trailing Twelve Months) | 60.66% |
| Revenue Per Share Growth | 5.63% |
| Revenue Growth (5 Year) | 21.03% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 22.58% |
| Total Debt (5 Year) | 16.03% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 35.83% |
| EPS Change (Trailing Twelve Months) | 32.51% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -80,298,000 |
| Net Debt (Last Fiscal Year) | -48,020,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 1 |
| Price to Sales (Trailing Twelve Months) | 1 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 17 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 17 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | -100,000 |
| Price to Book (Most Recent Quarter) | -100,000 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | -100,000 |
| Long Term Debt to Equity (Most Recent Quarter) | -100,000 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 0 |
| Current Ratio (Most Recent Quarter) | 0 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -234,156,000 |
| Free Cash Flow (Trailing Twelve Months) | -186,175,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -2 |
| Net Interest Coverage (Trailing Twelve Months) | -1 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | -100,000 |
| Total Debt to Equity (Most Recent Quarter) | -100,000 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -70.78% |
| Return on Assets (Trailing Twelve Months) | -68.45% |
| Return on Assets (5 Year) | -55.02% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -99,999.99% |
| Return on Equity (Trailing Twelve Months) | -99,999.99% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -194.81% |
| Return on Investment (Trailing Twelve Months) | -281.52% |
| Return on Investment (5 Year) | -115.31% |